Is BPC-157 FDA Approved? What the July 2026 Vote Really Means

Written by the NuLab Editorial Team · Published July 31, 2026 · Last reviewed July 31, 2026

A favorable advisory-committee vote moved BPC-157 one step forward in a pharmacy-compounding review. It did not approve BPC-157 as a drug or establish that it is safe and effective for human use.

Editorial scope: This article reports on an FDA advisory-committee meeting and publicly available regulatory evidence. It does not describe, recommend, or support the use of any NuLab product in humans. NuLab products are intended solely for laboratory research.

Quick answer: No. BPC-157 is not FDA approved. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding BPC-157 free base and BPC-157 acetate to the federal list of bulk substances that may be used in certain patient-specific compounded drugs. The recommendation is nonbinding. It is not a drug approval, it did not automatically change the list, and FDA must still complete its review and take further regulatory action.

In this guide

• What happened at the July 2026 FDA meeting?
• What the vote did not do
• What is the 503A Bulks List?
• What FDA staff found in the BPC-157 review
• Why did the committee reach a different conclusion?
• What happens next?
• BPC-157 FDA-status FAQs

What happened at the July 2026 FDA meeting?

The FDA convened its Pharmacy Compounding Advisory Committee, commonly called PCAC, on July 23 and 24, 2026. The committee considered seven peptide-related bulk drug substances over two days.

For BPC-157, FDA asked the committee to consider two chemically distinct substances:

• BPC-157 free base; and
• BPC-157 acetate.

The agency evaluated those substances in the context of possible inclusion on the Section 503A Bulks List. The use FDA reviewed was ulcerative colitis. That does not mean FDA determined that BPC-157 treats ulcerative colitis. It identifies the proposed use against which the agency evaluated the available chemistry, effectiveness and safety information.

The committee voted 8-6, with one abstention, to recommend adding the BPC-157 substances to the list, according to meeting coverage from the Associated Press and STAT. That recommendation went against FDA staff's written proposal, which concluded that the available information weighed against inclusion.

The disagreement is important. FDA's scientific reviewers and the outside advisory committee were examining the same regulatory question, but they reached different recommendations. FDA is now responsible for considering the vote, meeting discussion, public comments and its staff review before deciding what to do.

What the vote did not do

The fastest way to understand the news is to separate the actual vote from the conclusions being attached to it online.

It did not make BPC-157 an FDA-approved drug

FDA approval of a new drug ordinarily requires a formal application containing evidence about the product's quality, safety and effectiveness for a defined use. The July meeting did not review or approve a new drug application for BPC-157.

A place on the 503A Bulks List would address when eligible state-licensed pharmacies, federal facilities or physicians may use a bulk substance to prepare certain compounded drugs under federal law. It would not convert BPC-157 into an FDA-approved medicine.

Retatrutide illustrates the separate new-drug pathway: Phase 3 findings can support an FDA filing but do not themselves create an approval. See the Journal's review of retatrutide Phase 3 results and current FDA status.

It did not establish safety or effectiveness

The committee recommendation did not establish that BPC-157 is safe or effective for ulcerative colitis, injury recovery or any other condition. FDA staff expressly found the available human evidence insufficient to reach an effectiveness conclusion for the use it evaluated.

It did not approve products sold online

The vote concerned specified bulk substances in the pharmacy-compounding framework. It did not review, authorize or validate research products sold by individual vendors. It also did not determine that products marketed under the same common name are chemically interchangeable.

It did not automatically change federal compounding rules

Advisory committees provide expert recommendations. FDA states that their recommendations are nonbinding. The agency must still complete its evaluation and use the applicable regulatory process before the legal list changes.

What is the 503A Bulks List?

Section 503A of the Federal Food, Drug, and Cosmetic Act describes conditions under which certain patient-specific compounded drugs may qualify for exemptions from several requirements that otherwise apply to conventionally manufactured drugs.

FDA explains that a state-licensed pharmacist or physician generally may use a bulk drug substance under Section 503A only when the substance meets at least one of three pathways:

1. it complies with an applicable United States Pharmacopeia or National Formulary monograph;
2. if no applicable monograph exists, it is a component of an FDA-approved drug; or
3. if neither condition applies, it appears on the 503A Bulks List developed by FDA through regulation.

Additional conditions apply. Among them, the bulk substance must be accompanied by a valid certificate of analysis and manufactured by an establishment registered with FDA.

FDA's briefing document states that BPC-157 free base and BPC-157 acetate do not have an applicable USP or NF drug-substance monograph and are not components of an FDA-approved drug. That is why the list question matters to compounders.

The 503A pathway should not be confused with ordinary retail sales, laboratory research materials or FDA approval. These are separate legal and regulatory categories.

What FDA staff found in the BPC-157 review

FDA's 68-page BPC-157 briefing document examined four broad questions: chemical characterization, historical compounding use, available evidence of effectiveness and safety concerns.

1. The common name can hide meaningful chemical differences

FDA evaluated BPC-157 free base and BPC-157 acetate separately. Although the two names are often used loosely online, the agency explained that a free base and a salt are distinct bulk drug substances with different chemical structures and potentially different physical, chemical and biological properties.

FDA also identified inconsistencies in withdrawn nomination materials. The stated substance, Chemical Abstracts Service number, molecular information and certificates of analysis did not always point to the same form.

That finding has relevance beyond the compounding debate. A familiar product name is not a substitute for exact chemical identification, batch traceability and analytical testing. Learn how LC-MS identity testing and HPLC purity testing answer different questions.

2. The human evidence was limited

FDA reported finding five clinical studies that used BPC-157. The studies were small, short and used different methods. The agency said the authors often provided limited safety information and that safety monitoring was unclear in most of the reports.

FDA also found one registered Phase 1 study of an oral BPC-157 tablet. The record listed an estimated enrollment of 42 healthy participants, but no results had been posted and FDA could not identify an associated published study.

For ulcerative colitis—the use evaluated at the meeting—FDA identified one meeting abstract describing a multicenter randomized study. The agency found the report too limited to support a reliable conclusion about effectiveness.

FDA did not evaluate several other proposed uses because the nominations lacked enough information and the agency did not identify clinical studies in those populations. This is one reason broad online claims should not be inferred from the narrow question considered at the meeting.

3. Limited adverse-event data did not resolve the safety question

FDA found that no serious adverse events appeared to have been reported in the five small clinical studies it reviewed. The agency did not treat that finding as proof of safety because the studies were short, involved few participants and provided limited details about monitoring.

FDA also described three reports in its Adverse Event Reporting System involving injectable products identified as containing BPC-157. The reports included an injection-site reaction, shortness of breath and pigmentation changes. FDA emphasized that these reports had missing information and confounding factors, so they could not establish that BPC-157 caused the events.

That distinction matters in both directions: a spontaneous report is not proof of causation, while a small number of reports is not proof that a substance is safe.

4. FDA raised quality and immunogenicity concerns

Peptides can aggregate or degrade depending on their formulation, manufacturing process, impurities and storage environment. FDA said those factors could affect the safety profile of compounded BPC-157 products and could contribute to immune responses.

The agency was also concerned about peptide-related impurities and the difficulty of fully characterizing different substances marketed under the same common name.

These issues reinforce the importance of exact identifiers, lot-specific documentation and methods that answer more than one analytical question. Read how a vial's batch number should connect to its certificate of analysis.

FDA staff's recommendation

After weighing the chemistry, historical-use information, evidence and safety questions, FDA staff proposed not adding BPC-157 free base or BPC-157 acetate to the 503A Bulks List.

The staff review cited four central concerns:

• the substances were not adequately characterized;
• the human safety information was limited;
• possible immunogenicity and impurity risks remained unresolved; and
• the evidence was insufficient to conclude that BPC-157 was effective for ulcerative colitis.

Why did the committee reach a different conclusion?

An advisory committee is not the FDA staff. Its members hear agency presentations, outside speakers, public comments and one another's arguments before voting.

Public reporting from the meeting indicates that some members supporting inclusion placed weight on the possibility of moving peptide compounding into licensed pharmacies and physician-supervised settings. Members voting against inclusion emphasized the limited evidence, unresolved quality questions and risk that a favorable vote could be mistaken for an FDA finding of safety or effectiveness.

The vote therefore reflects a policy and regulatory recommendation—not the completion of the evidence review required for an approved drug.

This is also why the headline “FDA approves BPC-157” is inaccurate. The committee voted on possible inclusion of bulk substances in a compounding framework. It did not approve a branded product, a manufacturing process, a dose, a route of administration or a medical indication.

What happens next?

FDA's briefing document states that the agency will not make a final determination until it has considered the advisory process and completed its reviews.

FDA describes development of the 503A Bulks List as a notice-and-comment rulemaking process. That means the agency may publish a proposed regulatory action, accept public comments and then determine whether and how to finalize it. FDA may also issue or revise an interim enforcement policy while evaluation continues.

As of July 31, 2026:

• BPC-157 is not an FDA-approved drug;
• the advisory vote is nonbinding;
• the vote alone did not add BPC-157 to the 503A Bulks List; and
• FDA has not completed its final decision on the recommendation.

The status can change through later FDA action. Any future update should be checked against the agency's current compounding pages and Federal Register notices rather than inferred from social-media posts or sales claims.

BPC-157 FDA-status FAQs

Is BPC-157 FDA approved in 2026?

No. BPC-157 is not an FDA-approved drug. The July 2026 vote concerned whether two BPC-157-related bulk substances should be recommended for inclusion on a pharmacy-compounding list.

Did the FDA legalize BPC-157 on July 23, 2026?

No. An advisory committee made a nonbinding recommendation. The vote did not by itself change the 503A Bulks List, approve BPC-157 or authorize products offered by online vendors.

What was the BPC-157 vote?

The Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding BPC-157 free base and BPC-157 acetate to the 503A Bulks List.

Did FDA staff support the recommendation?

No. FDA staff proposed not adding the substances. Their briefing document cited characterization problems, limited human evidence, insufficient safety information and unresolved immunogenicity and impurity concerns.

Does a favorable 503A recommendation prove BPC-157 works?

No. A compounding-list recommendation is not a finding that a substance is safe and effective. FDA staff concluded that the available evidence was insufficient to determine effectiveness for the use evaluated.

Are BPC-157 free base and BPC-157 acetate the same thing?

They share the same active moiety, but FDA treats them as distinct bulk drug substances. Their chemical and physical properties may differ, which is why exact identification matters.

Can a committee recommendation be reversed or changed?

Yes. FDA considers the recommendation but is not legally bound by it. The agency can reach a different conclusion after reviewing the complete record.

The bottom line

The July 2026 vote was a meaningful regulatory development, but it was not FDA approval.

The accurate description is narrower: an outside advisory committee recommended that BPC-157 free base and BPC-157 acetate be added to a list used in the federal pharmacy-compounding framework. FDA staff opposed that recommendation, and the agency's final decision remains pending.

That distinction may sound technical, but it separates a developing policy decision from a claim the evidence does not support. BPC-157 remains unapproved, and the vote did not validate human use or any commercially available research product.

References

• U.S. Food and Drug Administration, July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.
• U.S. Food and Drug Administration, Briefing Document for BPC-157-Related Bulk Drug Substances.
• U.S. Food and Drug Administration, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.
• Associated Press, FDA Panel Narrowly Backs Unapproved Peptide Drugs.
• STAT, FDA Advisory Panel Backs Peptide Compounding Despite Staff Objections.

NuLab products are intended strictly for laboratory research and are not for human or animal consumption. This article provides regulatory reporting, not medical, legal, purchasing-for-personal-use or administration advice.